|
Post by centralcoastinvestor on Feb 3, 2018 15:38:48 GMT -5
For as much as some complain about MannKind and Mike Castagna not being transparent enough, I for one think they are doing a pretty good job of communicating the current targets of the company. It takes time to achieve paradigm changes in the diabetes market. I wish the share price was greater. But when you have entities that are willing to short one third of the outstanding shares, it is going to be very hard to move the price up.
But it seems to me, that if I was in Mike C.s shoes, I wouldn’t share everything that was in the works. It is very apparent to me that there are a lot of people out there that want to take MannKind down. So the last thing I would want is for them to know all that I was working on. In fact, I might even send out some information that was some misdirection. It wouldn’t surprise me if one day we get news that will be completely from left field. Some shareholders will complain that we should have been told. I say hogwash. As shareholders we need to know some things, but not everything. I actually don’t want to know everything, because our enemies would know too.
|
|
|
Post by sportsrancho on Feb 3, 2018 15:44:14 GMT -5
You speak the truth:-) It gets very very dark before the dawn for a good reason...
|
|
|
Post by dreamboatcruise on Feb 3, 2018 15:49:35 GMT -5
For as much as some complain about MannKind and Mike Castagna not being transparent enough, I for one think they are doing a pretty good job of communicating the current targets of the company. It takes time to achieve paradigm changes in the diabetes market. I wish the share price was greater. But when you have entities that are willing to short one third of the outstanding shares, it is going to be very hard to move the price up. But it seems to me, that if I was in Mike C.s shoes, I wouldn’t share everything that was in the works. It is very apparent to me that there are a lot of people out there that want to take MannKind down. So the last thing I would want is for them to know all that I was working on. In fact, I might even send out some information that was some misdirection. It wouldn’t surprise me if one day we get news that will be completely from left field. Some shareholders will complain that we should have been told. I say hogwash. As shareholders we need to know some things, but not everything. I actually don’t want to know everything, because our enemies would know too. Respectfully... you should never be CEO of a public company if you really hold these views. Perhaps you are just spinning to praise Mike.
|
|
|
Post by sportsrancho on Feb 3, 2018 16:34:01 GMT -5
imgur.com/a/TPNms It’s not hard to misdirect us:-) Not saying that was what that was at all! But people on ST will run with anything. Lol
|
|
|
Post by centralcoastinvestor on Feb 3, 2018 17:54:38 GMT -5
For as much as some complain about MannKind and Mike Castagna not being transparent enough, I for one think they are doing a pretty good job of communicating the current targets of the company. It takes time to achieve paradigm changes in the diabetes market. I wish the share price was greater. But when you have entities that are willing to short one third of the outstanding shares, it is going to be very hard to move the price up. But it seems to me, that if I was in Mike C.s shoes, I wouldn’t share everything that was in the works. It is very apparent to me that there are a lot of people out there that want to take MannKind down. So the last thing I would want is for them to know all that I was working on. In fact, I might even send out some information that was some misdirection. It wouldn’t surprise me if one day we get news that will be completely from left field. Some shareholders will complain that we should have been told. I say hogwash. As shareholders we need to know some things, but not everything. I actually don’t want to know everything, because our enemies would know too. Respectfully... you should never be CEO of a public company if you really hold these views. Perhaps you are just spinning to praise Mike. Respectfully, I disagree with you. Now I don’t think I’m CEO material but not because of these views I hold. I think very highly of Mike Castagna but am not intentionally spinning something to praise him. Lets say you are Mike and you are approached by an Amazon representative and that Amazon is interested in partnering with you in the future for Afrezza at first and other drugs to be later developed under their new pharmacy paradigm. However, you are one of a dozen or so companies that have been approached and they instruct you that this is top secret and cannot be shared. Now wouldn’t that be something that none of us would know about until later. Would you as CEO share this information? As far as misdirection, if I were Mike and another company approached me about further developing a drug with Technosphere. I might indicate that the drug had moved more to the back of the line while I worked out the details with the company. Particularly if the intended drug was going to step on a lot of toes. There are times you want as much of a head start as possible before the competition knows what you are up to.
|
|
|
Post by babaoriley on Feb 3, 2018 18:59:04 GMT -5
You speak the truth:-) It gets very very dark before the dawn for a good reason... Spoken like someone who knows. Out with it, Sports, what do you know?
|
|
|
Post by sportsrancho on Feb 3, 2018 19:07:53 GMT -5
You speak the truth:-) It gets very very dark before the dawn for a good reason... Spoken like someone who knows. Out with it, Sports, what do you know? I know enough CEOs to know that Central is right:-)
|
|
|
Post by liane on Feb 3, 2018 19:13:09 GMT -5
imgur.com/a/TPNms It’s not hard to misdirect us:-) Not saying that was what that was at all! But people on ST will run with anything. Lol Just shows again what a class act Mike is.
|
|
|
Post by straightly on Feb 4, 2018 0:29:44 GMT -5
Spoken like someone who knows. Out with it, Sports, what do you know? I know enough CEOs to know that Central is right:-) And Right can never be wrong.
|
|
|
Post by babaoriley on Feb 4, 2018 1:05:31 GMT -5
For as much as some complain about MannKind and Mike Castagna not being transparent enough, I for one think they are doing a pretty good job of communicating the current targets of the company. It takes time to achieve paradigm changes in the diabetes market. I wish the share price was greater. But when you have entities that are willing to short one third of the outstanding shares, it is going to be very hard to move the price up. But it seems to me, that if I was in Mike C.s shoes, I wouldn’t share everything that was in the works. It is very apparent to me that there are a lot of people out there that want to take MannKind down. So the last thing I would want is for them to know all that I was working on. In fact, I might even send out some information that was some misdirection. It wouldn’t surprise me if one day we get news that will be completely from left field. Some shareholders will complain that we should have been told. I say hogwash. As shareholders we need to know some things, but not everything. I actually don’t want to know everything, because our enemies would know too. Respectfully... you should never be CEO of a public company if you really hold these views. Perhaps you are just spinning to praise Mike. You can't say "respectfully, then say something mean to the person; many do, but it's still not right. Not to take anything away from your posting abilities, DBC, but that post sucked, like several of your others.
|
|
|
Post by centralcoastinvestor on Jun 7, 2018 13:58:27 GMT -5
I bet very few saw early completion of the Treprostinil Phase 1 study. I think there is a lot coming that we don’t know about yet. Management only needs to announce these events when they occur. As I stated in this thread, Mike is a savvy CEO and there is no point in giving the competition any heads up on what is being planned. I’m looking forward to an eventful June.
|
|
|
Post by boca1girl on Jun 7, 2018 14:13:37 GMT -5
I bet very few saw early completion of the Treprostinil Phase 1 study. I think there is a lot coming that we don’t know about yet. Management only needs to announce these events when they occur. As I stated in this thread, Mike is a savvy CEO and there is no point in giving the competition any heads up on what is being planned. I’m looking forward to an eventful June. I’m expecting something similar with the pediatric trials. If early trial results are excellent, couldn’t we be pleasantly surprised with an earlier than planned approval?
|
|
|
Post by mytakeonit on Jun 7, 2018 14:15:16 GMT -5
Well it looks like I'm not selling any of those MNKD shares that I bought to pay for my Japan trip !!!
|
|
|
Post by harryx1 on Jun 7, 2018 14:34:31 GMT -5
I bet very few saw early completion of the Treprostinil Phase 1 study. I think there is a lot coming that we don’t know about yet. Management only needs to announce these events when they occur. As I stated in this thread, Mike is a savvy CEO and there is no point in giving the competition any heads up on what is being planned. I’m looking forward to an eventful June. I’m expecting something similar with the pediatric trials. If early trial results are excellent, couldn’t we be pleasantly surprised with an earlier than planned approval?
|
|
|
Post by brotherm1 on Jun 7, 2018 15:16:13 GMT -5
Well it looks like I'm not selling any of those MNKD shares that I bought to pay for my Japan trip !!! . No. Save them for a trip to mars.
|
|